Ex-Pfizer drug reduces osteoarthritis pain in British biotech's phase 2 study

Levicept arose from the metaphorical ashes of Pfizer’s former R&D campus in the U.K. Now, the biotech has scored a phase 2 win for an osteoarthritis drug that can also be traced back to the Big Pharma.